@article{4e400ba4c7ee4bd58079fa1bddd5f777,
title = "Prescription patterns in patients with schizophrenia who discontinued long-acting injectable antipsychotics: A chart-review",
author = "Keisuke Asano and Takefumi Suzuki and Masaru Mimura and Hiroyuki Uchida",
note = "Funding Information: Dr Asano has received speaker's honoraria from Otsuka Pharmaceutical, Dainippon‐Sumitomo Pharma, Janssen Pharmaceuticals, and Yoshitomi Yakuhin within the past 3 years. Dr Suzuki has received manuscript or speaker's fees from Astellas, Dainippon Sumitomo Pharma, Eisai, Eli Lilly, Elsevier Japan, Janssen Pharmaceuticals, Kyowa Yakuhin, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, MSD, Novartis, Otsuka Pharmaceutical, Shionogi, Shire, Tsumura, Wiley Japan, and Yoshitomi Yakuhin, and research grants from Eisai, Mochida Pharmaceutical, Meiji Seika Pharma and Shionogi. Dr Mimura has received speaker's honoraria from Daiichi Sankyo, Dainippon‐Sumitomo Pharma, Eisai, Eli Lilly, Fuji Film RI Pharma, Janssen Pharmaceutical, Mochida Pharmaceutical, MSD, Nippon Chemipher, Novartis Pharma, Ono Yakuhin, Otsuka Pharmaceutical, Pfizer, Takeda Yakuhin, Tsumura, and Yoshitomi Yakuhin within the past 3 years. Also, he received grants from Daiichi Sankyo, Eisai, Pfizer, Shionogi, Takeda, Tanabe Mitsubishi, and Tsumura within the past 3 years. Dr Uchida has received grants from Eisai, Otsuka Pharmaceutical, Dainippon‐Sumitomo Pharma, and Meiji‐Seika Pharma; speaker's honoraria from Otsuka Pharmaceutical, Dainippon‐Sumitomo Pharma, Eisai, and Meiji‐Seika Pharma; and advisory panel payments from Dainippon‐Sumitomo Pharma within the past 3 years.",
year = "2021",
month = may,
doi = "10.1111/pcn.13211",
language = "English",
volume = "75",
pages = "184--185",
journal = "Psychiatry and Clinical Neurosciences",
issn = "1323-1316",
publisher = "Wiley-Blackwell",
number = "5",
}
